66th ASH Annual Meeting: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma

Symposia: Multiple Myeloma: Pharmacologic Therapies Oral and Poster Abstracts
Oral

Research, Clinical trials, Combination therapy, Adult, Drug development, Bispecific Antibody Therapy, Elderly, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, Study Population, Human, Measurable Residual Disease

Hall B (San Diego Convention Center)

Moderators:

Alissa Visram, MD, MPH, and Hamza Sloan Hashmi, MD,

Disclosures:

Visram: GSK: Honoraria; Janssen: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Forus Therapeutics: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Sanofi: Honoraria.

This Session Brings Phase 1 and Phase 2 Trials Introducing Drugs with New Mechanism of Action or New Combinations Being Disclosed For the First Time in Multiple Myeloma. The Session Contains New Immunotherapy Antibodies, Combinations with Bispecific T-Cell Engagers, Combinations with New CELMoDs and First Data Disclosure of Agents Exploring New Targets in Relapsed and Refractory Multiple Myeloma.

4:30 PM

1021

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, MD¹, Sheeba K. Thomas, MD², Amrita Y Krishnan, MD, FACP³, Jacob P. Laubach⁴^*, Adam D. Cohen, MD⁵, Suzanne Trudel, MD, MSc⁶, Luciano J. Costa, MD, PhD⁷, Nizar J. Bahlis, MD⁸, Peter A. Forsberg, MD⁹, Rayan Kaedbey¹⁰, Rafael Fonseca, MD¹¹, Andrew Spencer, MBBS¹²^*, Paula Rodríguez-Otero, MD, PhD¹³^*, Maria-Victoria Mateos, MD, PhD¹⁴, Chihunt Wong¹⁵^*, James Cooper¹⁵^*, Tulika Tyagi¹⁵^*, Rin Nakamura¹⁵^*, Voleak Choeurng¹⁵^* and Alexander M. Lesokhin, MD¹⁶

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²The University of Texas MD Anderson Cancer Center, Houston, TX
³Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Irvine, CA
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA
⁶Princess Margaret Cancer Centre, Toronto, ON, Canada
⁷O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
⁸Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
⁹University of Colorado School of Medicine, Aurora, CO
¹⁰Jewish General Hospital, McGill University, Montreal, QC, Canada
¹¹Mayo Clinic in Arizona, Phoenix, AZ
¹²Alfred Health-Monash University, Melbourne, VIC, Australia
¹³Clínica Universidad de Navarra, Pamplona, Spain
¹⁴Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
¹⁵Genentech, Inc., South San Francisco, CA
¹⁶Memorial Sloan Kettering Cancer Center, New York, NY

4:45 PM

1022

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis

Sikander Ailawadhi¹, Asher A. Chanan-Khan, MD², Jack Khouri, MD³, Costas K. Yannakou, MBBS, PhD⁴^*, Zi Chen, MD, PhD⁵^*, Yanyan Wang, MD⁵^*, Huanshan Guo, MD⁶^*, Hengbang Wang, PhD⁵^*, Mingyu Li, PhD⁷^*, Mohammad Ahmad, MD⁷^*, Dajun Yang, MD, PhD^5,7^* and Yifan Zhai, MD, PhD^5,6,7

¹Mayo Clinic, Jacksonville, FL
²Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
³Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁴Molecular Oncology and Cancer Immunology, Epworth HealthCare, Melbourne, VIC, Australia
⁵Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
⁶Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
⁷Ascentage Pharma Group Inc., Rockville, MD

5:00 PM

1023

Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Emma Searle, MD, PhD^1,2^*, Victoria Campbell, MD, PhD³^*, Charlotte Pawlyn, PhD^4,5, Ceri Bygrave, MBBCh MRCP FRCPath⁶^*, Sarah Gooding, MD, PhD⁷^*, James Cavet, PhD FRCP FRCPath¹^*, Matthew W. Jenner⁸^*, Vivek Radhakrishnan⁹^*, Steve Knapper, MRCP, FRCPath, DM¹⁰^*, Dima el-Sharkawi⁵^*, Jenny O'Nions¹¹^*, Tomasz Knurowski, MD¹²^*, Karen Clegg, PhD¹²^*, Will Henry West, PhD, MSc, MBA¹²^*, Debbie Haynes, BSc¹²^*, Kris Frese, PhD¹²^* and Tim Somervaille, PhD FRCP FRCPath¹

¹The Christie NHS Foundation Trust, Manchester, United Kingdom
²The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
³Department of Haematology, Western General Hospital, Edinburgh, United Kingdom
⁴Institute of Cancer Research, Sutton, United Kingdom
⁵The Royal Marsden NHS Foundation Trust, London, United Kingdom
⁶Department of Haematology, Cardiff & Vale University Health Board, Cardiff, United Kingdom
⁷MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, ENG, United Kingdom
⁸University Hospital Southampton, Southampton, United Kingdom
⁹University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
¹⁰Cardiff University School of Medicine, Cardiff, United Kingdom
¹¹Department of Haematology, University College London Hospital, London, United Kingdom
¹²CellCentric Ltd, Cambridge, United Kingdom

5:15 PM

1024

Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael H. Tomasson¹^*, Eli Gabayan²^*, Syed Abbas Ali³, Gabriel Afram⁴^*, Sona Ghorashi⁵^*, Trish Creel⁵^*, Luisa Paccagnella⁶^*, Carolyn Lou⁵^* and Ola Landgren⁷

¹Department of Internal Medicine, University of Iowa, Iowa City, IA
²Beverley Hills Cancer Center, Beverly Hills, CA
³Department of Oncology, The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
⁴Pfizer Inc, Solna, Sweden
⁵Pfizer Inc, New York, NY
⁶Pfizer Inc, Cambridge, MA
⁷Sylvester Comprehensive Cancer Center, Miami, FL

5:30 PM

1025

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Irwindeep Sandhu, MD¹^*, Paul G. Richardson², Albert Oriol³^*, Darrell White⁴, Richard Leblanc, MD, FRCPC⁵, Noopur Raje⁶, Enrique M. Ocio⁷, Aurore Perrot, MD, PhD⁸, Thierry Facon⁹^*, Cesar Rodriguez, MD¹⁰^*, Ralph Wäsch¹¹, Meletios A. Dimopoulos, MD¹², Tracy T. Chow¹³^*, Allison Gaudy¹³^*, Jing Gong¹³^*, Zehua Zhou¹³^*, Tiziana Civardi¹⁴^*, Joseph T. Hadala¹³^*, Yue Zhu¹³^*, Jessica Katz¹³ and Marc S. Raab¹⁵^*

¹University of Alberta, Edmonton, AB, Canada
²Dana-Farber Cancer Institute, Boston, MA
³Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
⁴Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
⁵Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Canada
⁶Massachusetts General Hospital, Boston, MA
⁷Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
⁸Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
⁹Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, Lille, France
¹⁰Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
¹¹Department of Medicine, University of Freiburg Medical Center, Freiburg, Germany
¹²National and Kapodistrian University of Athens, Athens, Greece
¹³Bristol Myers Squibb, Princeton, NJ
¹⁴Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
¹⁵Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany

5:45 PM

1026

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Hang Quach, MD, FRACP, FRCPA, MBBS¹, Bradley Augustson, MBBS, FRACP, FRCPA²^*, Hanlon Sia, MBBS FRACP FRCPA³^*, Nishi Shah, MBBS, MPH⁴, Eben I Lichtman, MD⁵, Michaela Liedtke, MD⁶, Camille Martinet⁷^*, Vinu Menon⁸^*, Andrew Garton, PhD⁹^*, Maria Pihlgren¹⁰^*, Beata Holkova, MD¹¹, Cyril Konto, MD⁸, Lida Pacaud, MD¹²^* and Amit Khot, MD, FRACP, FRCPath, MBBS, MRCP¹³^*

¹St. Vincent's Hospital Melbourne, East Melbourne, Australia
²Sir Charles Gairdner Hospital and Linear Clinical Research, Perth, Western Australia, Australia
³Pindara Private Hospital, Gold Coast, Australia
⁴Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
⁵Division of Hematology, University of North Carolina School of Medicine, Durham, MA
⁶Stanford University Cancer Center, Stanford, CA
⁷Medqualis, Montreal, Canada
⁸Ichnos Sciences, New York, NY
⁹Ichnos Sciences Inc., New York
¹⁰Ichnos Sciences SA, Epalinges, Switzerland
¹¹Ichnos Sciences Inc, New York
¹²Ichnos Sciences Inc., New York, NY
¹³Peter MacCallum Cancer Center, Melbourne, VIC, AUS

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

654A.O2.6 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma